The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer

Ronan Chaligné, Tatiana Popova, Marco-Antonio Mendoza-Parra, Mohamed-Ashick M. Saleem, David Gentien, Kristen Ban, Tristan Piolot, Olivier Leroy, Odette Mariani, Hinrich Gronemeyer, Anne Vincent-Salomon, Marc-Henri Stern, and Edith Heard

1 Centre de Recherche, Institut Curie, 75248 Paris Cedex 05, France; 2 Centre National de la Recherche Scientifique, Unité Mixte de Recherche 3215, Institut Curie, 75248 Paris Cedex 05, France; 3 Institut National de la Santé et de la Recherche Médicale U934, Institut Curie, 75248 Paris Cedex 05, France; 4 Equipe Labellisée Ligue Contre le Cancer, UMR3215, 75248 Paris Cedex 05, France; 5 Institut National de la Santé et de la Recherche Médicale U830, Institut Curie, 75248 Paris Cedex 05, France; 6 Institut de Génétique et de Biologie Moléculaire et Cellulaire, Equipe Labellisée Ligue Contre le Cancer, Centre National de la Recherche Scientifique UMR 7104, Institut National de la Santé et de la Recherche Médicale U964, University of Strasbourg, 67404 Illkirch Cedex, France; 7 Department of Tumor Biology, Institut Curie, 75248 Paris Cedex 05, France; 8 Plate-forme d’Imagerie Cellulaire et Tissulaire at BDD

Disappearance of the Barr body is considered a hallmark of cancer, although whether this corresponds to genetic loss or to epigenetic instability and transcriptional reactivation is unclear. Here we show that breast tumors and cell lines frequently display major epigenetic instability of the inactive X chromosome, with highly abnormal 3D nuclear organization and global perturbations of heterochromatin, including gain of euchromatic marks and aberrant distributions of repressive marks such as H3K27me3 and promoter DNA methylation. Genome-wide profiling of chromatin and transcription reveal modified epigenomic landscapes in cancer cells and a significant degree of aberrant gene activity from the inactive X chromosome, including several genes involved in cancer promotion. We demonstrate that many of these genes are aberrantly reactivated in primary breast tumors, and we further demonstrate that epigenetic instability of the inactive X can lead to perturbed dosage of X-linked factors. Taken together, our study provides the first integrated analysis of the inactive X chromosome in the context of breast cancer and establishes that epigenetic erosion of the inactive X can lead to the disappearance of the Barr body in breast cancer cells. This work offers new insights and opens up the possibility of exploiting the inactive X chromosome as an epigenetic biomarker at the molecular and cytological levels in cancer.

[Supplemental material is available for this article.]

There is increasing evidence that epigenetic modifications, such as changes in DNA methylation, chromatin structure, noncoding RNAs, and nuclear organization, accompany tumorigenesis (De Carvalho et al. 2012; for review, see Shen and Laird 2013). Even tumors with relatively normal karyotypes can show dramatically perturbed nuclear structures (Huang et al. 1997; for review, see Zink et al. 2004). In theory, epigenetic changes could lead to inactivation of tumor suppressor genes, aberrant expression or function of oncogenes, or more global gene expression changes that perturb genome function, thereby contributing to cancer progression. However, despite the possible use of epigenetic changes as prognostic markers (Elshiekh et al. 2009) or even as therapeutic targets (e.g., Schenk et al. 2012; Zhang et al. 2012), the full extent of epigenetic changes in cancer remains poorly explored.

The inactive X chromosome (Xi), also known as the Barr body, provides an outstanding example of an epigenetic nuclear landmark that is disrupted in cancer. The disappearance of the Barr body in breast tumors was noted many decades ago (Barr and Moore 1957; Perry 1972; Smethurst et al. 1981). To date, only genetic instability had been clearly demonstrated as a cause for Barr body loss (Ganesan et al. 2002; Sirchia et al. 2005; Vincent-Salomon et al. 2007; Xiao et al. 2007; and for review, see Pageau et al. 2007). Past work had implicated BRCA1, a major hereditary factor predisposing to breast and ovarian cancer development and a key player in the maintenance of genome integrity (for review, see O’Donovan and Livingston 2010), in promoting XIST RNA coating of the Xi and its epigenetic stability (Ganesan et al. 2002; Silver et al. 2007). However, subsequent work in BRCA1-deficient tumors indicated that Barr body loss was usually due to genetic loss of the Xi and duplication of the Xa rather than to Xi reactivation and epigenetic instability (Sirchia et al. 2005; Vincent-Salomon et al. 2007; Xiao et al. 2007). BRCA1-deficient cancers are usually of the basal-like carcinoma (BLC) subtype, a high-grade, genetically unstable, invasive ductal carcinoma. Indeed, when the genetic status of the X chromosome was explored in BLCs (Richardson et al. 2006), genetic instability/loss of the Xi was found to be a frequent event in both sporadic and BRCA1−/− associated BLCs. Luminal (A and B, expressing
hormonal receptors) and HER2 (encoded by ERBB2) amplified molecular subtypes of invasive ductal carcinoma are more genetically stable and show less frequent loss of the inactive X chromosome (Perou et al. 2000; Turner and Reis-Filho 2006). However, little is known about the epigenetic status of the inactive X in breast cancers and the extent to which epigenetic instability might account for Barr body disappearance in some cases.

X-chromosome inactivation (XCI) ensures dosage compensation for X-linked gene products between XX females and XY males (Lyon 1961). It is a developmentally regulated process that depends on the action of a noncoding RNA, Xist (X-inactive-specific transcript), which becomes up-regulated on one of the two X chromosomes, coating it in cis and inducing gene silencing. Xist RNA accumulation on the future inactive X rapidly creates a silent nuclear compartment that is depleted of RNA Polymerase II (RNA Pol II), transcription factors, and transcription (as detected by Cot-1 RNA). X-linked genes become repressed during the early stages of XCI (Chaumeil et al. 2006; Clemson et al. 2006; Chow et al. 2010). Xist RNA also induces a cascade of chromatin changes, involving Polycomb group proteins and other complexes, and results in various histone modifications, such as the hypoacetylation of histones 3 and 4, trimethylation of histone 3 lysine 27 (H3K27me3), and the loss of di- and trimethylation at histone 3 lysine 4 (H3K4me2/3) (Csankovszki et al. 1999; Heard et al. 2001; Boggs et al. 2002). Promoter DNA methylation of X-linked genes occurs downstream from Xist RNA coating, with gene-specific timing of promoter methylation (Gendrel et al. 2013). The Xi adopts a unique three-dimensional (3D) chromatin organization that is dependent on Xist RNA (Splinter et al. 2011; for review, see Chow and Heard 2010). Furthermore, the chromatin landscape of the inactive X has been investigated in adult human cells and seems to be divided into large blocks of H3K9me3 or H3K27me3 (Chadwick 2007; Chadwick and Willard 2004). In somatic cells, the majority of X-linked genes are stably repressed on the Xi, with spontaneous reactivation of single genes being observed at a frequency of <10−8, presumably due to synergistic epigenetic mechanisms (Csankovszki et al. 2001). However, a subset of genes can escape XCI in somatic cells (Carrel and Willard 2005; Kucera et al. 2011; Cotton et al. 2013). In cancer, aberrant escape from XCI has previously been speculated to occur (Pageau et al. 2007; Agrelo and Wutz 2010; Carone and Lawrence 2013; Yildirim et al. 2013). However, the extent to which the normally stable epigenetic state of the Xi is perturbed in cancer has never been systematically explored.

The X chromosome is of interest from a cancer perspective. First, several of the approximately 1000 genes located on the X have been implicated in cancer, including the cancer/testis (C/T) genes (Grigoriadis et al. 2009); tumor suppressors such as AMER1 (also known as WTX), FOXP3 (Bennett et al. 2001; Rivera et al. 2007); chromatin remodelers related to disease, e.g., ATRX; or chromatin modifying factors, e.g., KDM6A (also known as UTX), PHF8, HDAC8 (Nakagawa et al. 2007; for reviews, see Agrelo and Wutz 2010; Portela and Esteller 2010). A few of these genes are known to escape X inactivation in normal cells (e.g., KDM6A), but most are normally stably repressed on the inactive X. In the cases of AMER1 and FOXP3, tumorigenesis has been linked to clonal expansion of cells in which the wild-type copy is on the inactive X in female patients heterozygous for a mutation (Bennett et al. 2001; Rivera et al. 2007).

Although reactivation of X-linked genes has been previously hypothesized to occur in a cancer context (Spatz et al. 2004), few actual examples have been reported, presumably due to the technical challenges in specifically detecting the Xi. For example, deletion of Xist was reported to lead to hematological dysplasia and leukemia in mice; however, the allele-specific transcriptional activity of the inactive X chromosome and its heterochromatin structure were not examined (Yildirim et al. 2013). In another study, reactivation of the X-linked MPP1 gene and disrupted XIST expression were reported in an ovarian cancer cell line (Kawakami et al. 2004). In breast tumors, DNA hypomethylation and abnormal expression of a single X-linked gene analyzed, VBP1, was detected on the Xi (Richardson et al. 2006). A systematic analysis of the transcriptional and epigenetic status of the Xi in breast tumors has been lacking however. Here we perform an integrated analysis of gene expression, chromatin status, and nuclear organization of the inactive X chromosome in breast cancer, using allele-specific and single-cell approaches.

**Results**

**Aberrant nuclear organization of the inactive X chromosome in breast cancer cells**

To evaluate the status of the inactive X chromosome in different types of breast cancer, we selected three cell lines that represent the main breast cancer molecular subtypes: ZR-75-1 (luminal), SK-BR-3 (HER2+), and MDA-MB-436 (Basal-Like Carcinoma [BLC], BRCA1 null). WI-38 (embryonic lung fibroblasts) and Human Mammary Epithelial Cells (HMECs) were analyzed in parallel as nonmalignant ("normal") female primary cells. Using RNA FISH, we found that ZR-75-1 and MDA-MB-436 cell lines possess one XIST RNA domain, whereas SK-BR-3 cells have two domains. X-chromosome paint DNA FISH combined with XIST RNA FISH, and 3D microscopy revealed that XIST RNA signals overlapped to a great extent with the X chromosome DNA in both normal and tumor cell lines. However, punctate XIST RNA signals beyond the X-chromosome territory could be detected in the tumor cell lines, particularly in ZR-75-1 and MDA-MB-436 (Fig. 1A; Supplemental Fig. S1A). RT-qPCR revealed that XIST was expressed at slightly lower levels in the tumor cell lines, and the associated RNA FISH signal was slightly weaker and was more dispersed in the breast cancer cell lines (Supplemental Fig. S1B,C,E). Importantly, all of the tumor cell lines revealed a markedly weaker DNA enrichment of the Barr body (Supplemental Fig. S1D,E).

Given the complex genomes of breast cancer cells, we investigated the precise genetic constitution of the active and inactive X chromosomes using single nucleotide polymorphism array (Human SNP Array 6.0) analysis and DNA FISH (Fig. 1B; Supplemental Fig. S1F). ZR-75-1 contains three X-chromosome segments, each carrying an XIC/XIST locus, but XIST RNA coated only one of them, suggesting the presence of two Xa chromosomes and one Xi (in agreement with allelic imbalance of the XIC locus). Sk-BR-3 possesses four X-chromosome fragments, each with an XIC locus, but only two are associated with XIST RNA. MDA-MB-436 displayed the most complex situation, with six X-chromosome fragments visible by DNA FISH on metaphase spreads, but with only two XIC loci and one XIST RNA domain (Fig. 1A,B; Supplemental Fig. S1F). We also evaluated X-chromosome constitution in these cell lines through the expression of two X-linked genes: KDM5C, known to escape from XCI, and HUWE1, subject to XCI (Cotton et al. 2013). Our observations concur with the expected expression profiles in the two normal and three cancer cell lines, i.e., KDM5C is expressed from all X chromosome fragments that carried the gene, and HUWE1 is
expressed only from the non-\textit{XIST} RNA-coated X fragments that carried it (Supplemental Fig. S1G). Thus, all three tumor cell lines contain at least one fragment of an Xi chromosome.

We then investigated whether \textit{XIST} RNA-coated Xi fragments were depleted for RNA Pol II and Cot-1 RNA as previously described for the Xi in female somatic cells (Chaumeil et al. 2006; Clemson et al. 2006; Chow et al. 2010). In WI-38 and HMEC cells, both Cot-1 RNA and RNA Pol II were excluded from the \textit{XIST} domain, which was associated with a DAPI-dense, heterochromatic Barr body. However, all tumor cells showed a
frequent absence of a DAPI-dense Barr body and a defective depletion of Cot-1 RNA and RNA Pol II within the XIST domain (Fig. 1C; Supplemental Figs. S1H–K, S2A,C). Together, these results reveal major aberrations of nuclear organization and chromosome condensation of the XIST RNA-coated X chromosome in breast cancer cells.

**Aberrant chromatin hallmarks of the inactive X chromosome in breast cancer cell lines**

We next investigated whether heterochromatic hallmarks of the Xi were preserved. Detection of H3K27me3 by IF combined with XIST RNA FISH revealed a marked lack of H3K27me3 enrichment at the XIST-coated chromosome in all three tumor cell lines (Fig. 2A). In HMECs, H3K27me3 is about twofold more enriched on the Xi than on the non-XIST-coated genome (Fig. 2B; Supplemental Fig. S2A,B). In tumor cells, the lowest enrichment was found in ZR-75-1 and MDA-MB-436 with a median of 1.25 and 1.37-fold, respectively, whereas for SK-BR-3 it is 1.68 (Fig. 2A,B; Supplemental Fig. S2I). Decreased H3K27me3 enrichment at the XIST domain was further supported by super resolution structured illumination microscopy (SIM) (Fig. 2C). Indeed, ZR-75-1 and MDA-MB-436 showed the lowest degree of XIST and H3K27me3 colocalization with a Pearson colocalization coefficient of 0.15, whereas SK-BR-3 had a coefficient at 0.35. HMEC and WI-38 displayed colocalization coefficients of 0.44 and 0.45, respectively (Supplemental Fig. S2D).

Depletion of euchromatic histone modifications is another hallmark of the Xi. Using IF combined with XIST RNA FISH, we found that H3K9 and H4 acetylation were present within the XIST RNA domain in tumor cells in contrast to normal cells (Fig. 2D,E; Supplemental Fig. S2E,F,I). The H3K4me2 mark was less perturbed, being globally absent from the Xi, except in ZR-75-1 cells (Supplemental Fig. S2E,F,H). Similar results were obtained for H3K4me3 staining (with, for example, median at 0.69 and 0.71, respectively, for HMEC and MDA-MB-436) (data not shown). Closer examination by SIM revealed that H3K9ac and XIST RNA signals were intermingled in the majority of breast cancer nuclei (Fig. 2F), whereas H3K4me2 was largely but not completely depleted within the XIST RNA compartment (Supplemental Fig. S2I). SIM of RNA Pol II also revealed substantial intermingled overlap with XIST RNA domains (Supplemental Fig. S2K). Thus, there is a major disruption of chromatin hallmarks over the XIST RNA-coated chromosome, most strikingly in ZR-75-1 and MDA-MB-436 cell lines. We confirmed that XIST is always expressed from only one allele, excluding the possibility of aberrant XIST expression and coating of the Xa instead of the Xi (Supplemental Fig. S3A). In summary, the heterochromatic structure of the Xi is disrupted in the three tumor cell lines to variable extents. The variability in Xi perturbation between cells was not found to be linked to a specific stage of the cell cycle (Supplemental Fig. S3B–D). Furthermore, the global levels of histone modifications in the different cell lines did not correlate with the aberrant chromatin status of the Xi (Supplemental Fig. S3B).

To specifically compare the chromatin status of the Xi and Xa in the tumor cell lines, we used metaphase spreads to monitor chromatin marks by IF followed by X-chromosome paint DNA FISH as described (Fig. 3; Keohane et al. 1996; Chaumeil et al. 2002). In all tumor cell lines, we could readily distinguish Xa from Xi fragments using H3K27me3, H4ac, and H3K4me2 (Fig. 3A–C). The only exception was MDA-MB-436, where from the two main Xi fragments, only the XIC-linked (and XIST-coated) fragment is enriched for H3K27me3 (Fig. 3C,D; Supplemental Fig. S3F), whereas the other (non-XIC-linked) X fragment lacked H3K27me3 enrichment, although it was still depleted for H4ac and H3K4me2. Thus, the XIC is required for H3K27me3 enrichment but is dispensable for depletion of euchromatin marks on the Xi in these cancer cells (Fig. 3A,B). We also noted from the analysis of metaphase spreads that in MDA-MB-436 and SK-BR-3 cells, where the Xi is translocated to an autosomal region, H3K27me3 enrichment was seen beyond the X chromosome paint signal, implying that it can spread aberrantly into autosomal regions (Fig. 3C).

**Reactivation of X-linked genes on the inactive X chromosome in breast cancer cell lines**

We next assessed whether the heterochromatic disruption of the Xi observed in breast tumor cell lines corresponded to aberrant abnormal transcriptional activity from the Xi. To take advantage of SNPs that lie within introns of genes, we used an allele-specific transcriptional analysis based on nascent RNA hybridization to Human SNP Array 6.0 (henceforth called RNA SNP6) (Fig. 4A,B; Supplemental Fig. S4A; Gimelbrant et al. 2007). Due to the randomness of the XCI, clonal populations of cells are required to investigate Xi status. This was the case for all three tumor cell lines and for subclones derived from primary WI-38 cells (Supplemental Fig. S4B–E). In both WI-38 clones and the tumor cell lines, we saw the expected overall biallelic expression from autosomal regions (Chromosome 2 is shown as an example in Fig. 4A; Supplemental Fig. S4F). On the other hand, the X chromosome showed a globally monoallelic expression pattern in WI-38 clones, with the exception of genes in the pseudoautosomal regions that are known to behave as autosomes and to escape fully from XCI (Fig. 4B; Supplemental Fig. S4G). In tumor cells, we observed a generally monoallelic expression pattern from the X chromosome, although several regions showed biallelic expression, particularly in MDA-MB-436 cells (Fig. 4B). A gene-based analysis detected several previously described X-linked escapees (including DHRXS, TRAPP2C, CD99, or KDM6A) (Carrel and Willard 2005; Kucera et al. 2011; Coton et al. 2013), confirming the efficiency of this approach. We used known escapees and genes subject to XCI (Carrel and Willard 2005; Coton et al. 2013) to define a threshold to consider that a given X-linked gene is expressed from inactive and active alleles. Thus, we defined “cancer-specific” escapees as genes reactivated in at least one of the three cancer cell lines, but strictly expressed from the Xa in WI-38 clones and/or identified previously as subject to XCI (Fig. 4C). With these stringent criteria, we identified five, five, and nine “cancer-specific” escapees in the ZR-75-1, SK-BR-3, and MDA-MB-436 cell lines, respectively. To increase the number of informative X-linked genes evaluated, we also performed an RNA-seq analysis on mRNA from two additional WI-38 clones and the three tumor cell lines. We identified six, one, and 15 “cancer-specific” escapees in the ZR-75-1, SK-BR-3, and MDA-MB-436 lines, respectively (Fig. 4D). We validated XI-linked reactivation for several of these genes (Supplemental Figs. S4H–I, S5A). In conclusion, although RNA SNP6 and RNA-seq analyses do not necessarily reveal exactly the same “cancer-specific” escapees (15%–23% overlap was found, depending on cell line) due to the different SNPs assessed by the two methods (mainly intronic and mainly exonic, respectively), the combination of both techniques allowed us to identify 10 (9% of informative X-linked genes), five
(8%), and 20 (13%) Xi-linked genes as being abnormally reactivated in ZR-75-1, SK-BR-3, and MDA-MB-436 cell lines, respectively (Fig. 4E; Supplemental Table S1).

The preceding allele-specific analysis could not identify genes that are fully silenced in somatic cells and reactivated from only one allele in cancer cells, such as members of the C/T antigen

Figure 2. H3K27me3 and H3K9ac profiles associated with XIST-coated X chromosomes are impaired in breast cancer cell lines. (A) Z-projections of 3D immuno-RNA FISH show representative examples of the level of H3K27me3 enrichment (green) on XIST RNA domains (red) in normal (WI-38 and HMEC) and breast cancer cell lines (ZR-75-1, SK-BR-3, and MDA-MB-436). NB: In MDA-MB-436, the highly H3K27me3 enriched bodies visible in each nucleus do not belong to the X chromosome (nor in metaphase [Fig. 3C] or in interphase [Supplemental Fig. S3F]). (B) Boxplot shows the levels of H3K27me3 enrichment on XIST domains relative to the rest of the nucleus. Numbers of analyzed nuclei are shown above the x-axis. For details on quantification method see Supplemental Figure S2A,B. (C) High-resolution immuno-RNA FISH shows representative examples of H3K27me3 enrichment (green) on XIST RNA domains (red) in normal and breast cancer cell lines. Insets for H3K27me3, XIST RNA, and merge are shown below each cell line. (D) Single section of 3D immuno-RNA FISH shows representative examples of the level of H3K9ac depletion (green) on XIST RNA domains (red) in normal and breast cancer cell lines. (E) Boxplot shows the levels of H3K9ac depletion on XIST domains relative to the rest of the nucleus. The numbers of analyzed nuclei are shown above the x-axis. For details on quantification method, see Supplemental Figure S2A,C. (F) High-resolution immuno-RNA FISH shows representative examples of H3K9ac depletion (green) on XIST RNA domains (red) in normal and breast cancer cell lines. Insets for H3K9ac, XIST RNA, and merge are shown below each cell line. (Boxplots) Upper whisker represents 90%, upper quartile 75%, median 50%, lower quartile 25%, and lower whisker 10% of the data set for each cell line. (∗∗∗) P < 0.001; (∗∗) P < 0.01; (∗) P < 0.05 using the Student’s t-test. All data sets are compared with HMEC data set. Scale bar, 5 µm.
Figure 3. The inactive X chromosome is still epigenetically distinguishable from its active counterpart. (A) Representative examples of immunofluorescence show the status of H4ac (white) depletion/enrichment on X chromosomes (X-paint DNA FISH, red) on metaphase spreads from normal (WI-38) and breast cancer cell lines (ZR-75-1, SK-BR-3, and MDA-MB-436). On the right, MDA-MB-436 cells carry six X-chromosome fragments with a “2-by-2” homology, as assessed by the presence or absence of the NXT2 (white) or XIC loci (green), and line scans show H4ac enrichment variation between these X-fragments and the neighboring autosomal regions. As expected, one X chromosome (Xi) lacks H4ac staining in normal WI-38 cells (and HMEC, not shown). ZR-75-1 and SK-BR-3 cell lines harbor a reduced H4ac staining on one and two X chromosomes, respectively, in agreement with the number of XIST-coated X chromosomes shown in Figure 1A. In MDA-MB-436 cells, homologous X-chromosome fragments (two containing the XIC locus, two containing the NXT2 locus, and two with none of them) display opposite H4ac staining, suggesting that there is still one inactive and one active X chromosome linked to those loci, although fragmented. (B) Representative examples of immunofluorescence show the status of H3K4me2 (white) depletion/enrichment on X chromosomes (X-paint DNA FISH, red) on metaphase spreads from normal and breast cancer cell lines. On the right, line scans show H3K4me2 enrichment variation between the six X-fragments (for details, see A) and the neighboring autosomal regions in MDA-MB-436 cells. In each tumoral cell line, H3K4me2 depletion patterns follow the H4ac profiles found in A. (C) Representative examples of immunofluorescence show the status of H3K27me3 (white) enrichment on X chromosomes (X-paint DNA FISH, red) in metaphase spreads from breast cancer cell lines. ZR-75-1 and SK-BR-3 cell lines harbor an accumulation of H3K27me3 on one and two X chromosomes, respectively, in agreement with the number of XIST-coated X chromosomes shown in A. In MDA-MB-436 cells, H3K27me3 staining was only enriched on the X-chromosome fragment, where the XIC region lies. Indeed, RNA/DNA FISH analysis showed that this X fragment corresponds to the one coated by XIST RNA in interphase cells, which is not the case for the other fragments (Supplemental Fig. S3F). In SK-BR-3 and MDA-MB-436 cell lines, H3K27me3 spreads into the autosomal fragments translocated to the XIC-containing fragment. (D) Schematic view of H4ac, H3K4me2, and H3K27me3 patterns on X-chromosomes in the three tumor cell lines.
family that show aberrant expression in cancer cells (Grigoriadis et al. 2009). By assessing the overall expression of C/T members, we found increased expression of several C/T antigens in the cancer cell lines but not in normal cells (Supplemental Fig. S5B). For one C/T antigen gene (MAGEA6), we used RNA FISH to show that this aberrant expression usually originated from the inactive X chromosome.

Figure 4. Abnormal reactivation of the inactive X chromosome in breast cancer cell lines. (A,B) RNA SNP6 analysis shows the expression status of an autosomal chromosome, as example Chromosome 2 (A), and the X chromosome (B) in normal (WI-38) and breast cancer cell lines (ZR-75-1, SK-BR-3, and MDA-MB-436). Red bars indicate biallelic expression, and blue bars indicate monoallelic expression. The bar length represents the number of expressed informative SNPs on a 50-SNP sliding window. Gray rectangles correspond to noninformative regions due to loss of heterozygosity (LOH). Two WI-38 subclones (#1 and #28), carrying an inactive X chromosome of opposite parental origin, show clear monoallelic expression from either the maternal or paternal X chromosome confirming the clonality of the subclones (see Supplemental Fig. S4B). Allele-specific PCR analysis also confirmed the clonality of the three breast tumor cell lines (see Supplemental Fig. S4C–E). (C) RNA SNP6 analysis shows levels of X-linked gene allelic expression. X-linked genes known as subject to XCI (Carrel and Willard 2005; Cotton et al. 2013) and/or considered as monoallelically expressed in WI-38 clones (i.e., for each informative gene, <2/3 of the SNPs were observed as biallelically expressed) are shown on the boxplots. (D) RNA-seq analysis shows levels of X-linked gene allelic expression. X-linked shown on the boxplots are known to be subject to XCI (Carrel and Willard 2005; Cotton et al. 2013) and/or are considered as monoallelically expressed in WI-38 clones (i.e., for each informative gene, the allelic expression ratio is <40, i.e., expressed <20% on one of the two alleles). (E) Summary of the informative genes identified by the RNA SNP6 and RNA-seq approaches. Genes “known as subject to XCI” or “known to escape from XCI” refer to previous studies (Carrel and Willard 2005; Cotton et al. 2013). WI-38 data correspond to the two clones.
active rather than the inactive X in tumor cells (Supplemental Fig. S3C).

In order to assess allelic expression of specific genes at the single-cell level, we developed RNA FISH probes for several X-linked escapee genes, bypassing the issue of uninformative SNPs. We confirmed that HDAC8 is expressed from the XIST RNA-associated Xi chromosome only in MDA-MB-436 and SK-BR-3 cells (Supplemental Fig. S5D), whereas TBL1X was expressed from Xi only in ZR-75-1 (Fig. 5A). We also confirmed that APOO and SYTL4 are only escaping from XCI in MDA-MB-436 by RNA FISH (data not shown). ATRX was used as a control gene that is subject to XCI in all five cell lines (Supplemental Fig. S5E).

We then investigated the degree to which reactivation could impact on gene dosage for TBL1X, one of the “cancer-specific” escapees in ZR-75-1 cells. Using IF against TBL1X combined with RNA FISH, we correlated the protein levels of TBL1X to its expression from the Xi (Fig. 5B). On average, in ZR-75-1, the IF signals appear highly heterogeneous but also stronger than the four other cell lines (in agreement with the RNA level) (Fig. 5C; Supplemental Fig. S5F). We noted that MDA-MB-436 cells also showed slightly increased protein levels, consistent with overall TBL1X expression levels in this cell line, which must be due to higher expression of the single active allele (on the Xa) in this cell line. To determine whether the higher protein levels in ZR-75-1 are due to reactivation of TBL1X on the Xi or to overexpression of the active alleles on the Xa (as in MDA-MB-436), we quantitated the IF signal in cells that do, or do not, show TBL1X transcriptional reactivation on the Xi (Fig. 5D). Significantly more TBL1X staining was seen in ZR-75-1 nuclei that displayed TBL1X reactivation (Fig. 5E). We also sorted ZR-75-1 cells by FACS based on TBL1X staining intensity (Fig. 5F) and observed significantly more biallelic expression of TBL1X in cells with the highest levels of TBL1X protein staining (Fig. 5G).

Local epigenetic erosion affects genes that escape XCI in cancer

To investigate further the underlying causes of Xi gene reactivation in cancer cells, we investigated the chromatin status of “cancer-specific” escapees at the molecular level. First, the DNA methylation status of multiple X-linked gene promoters was investigated using EpiTYPER analysis (Sequenom) (Supplemental Fig. S6A). All escapees (normal or “cancer-specific”) showed low levels of DNA methylation at their promoters (e.g., KDMSC, HDAC8). However, we noted that some genes subject to XCI (i.e., only expressed from the Xa) in cancer cell lines, nevertheless showed low promoter methylation (e.g., TBL1X in SK-BR-3 cells or HDAC8 in ZR-75-1). This suggests that they might be more prone to reactivation in a cancer context, with outright reexpression from the Xi in only some cell lines.

We also performed chromatin immunoprecipitation and sequencing (ChIP-seq) on normal and cancer cell lines to assess Xi chromatin status. We investigated H3K27me3 (associated with the inactive state of the Xi), H3K4me3 (enriched at transcriptional start sites [TSS] of active genes), and RNA Pol II. The comparison of quantile-normalized H3K27me3 profiles revealed major changes for the X chromosomes between normal and tumor cells (Fig. 6A). In HMECs, low-resolution chromosome-wide profiles exhibited a pattern of domains that is highly reminiscent of the distinct nonoverlapping regions of the human Xi previously reported for H3K9me3 and H3K27me3 (Chadwick 2007; Chadwick and Willard 2004). Indeed, comparing the H3K9me3 and H3K27me3 data from the ENCODE Project Consortium (2012) with our H3K27me3 ChIP-seq data sets, these different types of heterochromatin domains are readily detectable in normal HMEC and WI-38 cells (Supplemental Fig. S6C; data not shown). In contrast, the organization of these H3K27me3-enriched domains was found to be heavily perturbed in ZR-75-1 and MDA-MB-436. In ZR-75-1 cells, the X chromosome displays a global, nearly uniform pattern of H3K27me3, with no discernable enriched domains (Fig. 6A). The analyzable parts of the X in SK-BR-3 cells (where an Xi is retained) are much less perturbed, apparently respecting the H3K27me3 domains. These results are in line with the reorganization of the Xi in interphase cells by IF/FISH (Fig. 2A–C). The X chromosome in MDA-MB-436 shows a heavily segmented H3K27 methylation profile, as (1) the beginning of the short arm shows no H3K27me3 marks (evident consequence of the loss of the Xi fragment); (2) the rest of the short arm displays significant H3K27me3 enrichment, although the profile is rather different from that seen for HMEC; (3) the region surrounding the XIC shows a profile similar to that seen in normal cells; and (4) the region spanning Xq21.33 to the end of the long arm, which is no longer linked to the XIC (see Fig. 3), does not display discernable H3K27me3 domains; in particular, the two highly enriched domains visible in normal cells are lacking (Fig. 6A, red dotted rectangles). To further consolidate these observations, we compared the variation of H3K27me3 signals along the X chromosome between HMEC and the other four cell lines (WI-38 and the three tumor cell lines). Highly variable H3K27me3 patterns across the X chromosome were observed in the tumor cell lines, and several regions for which an Xi copy was still present showed a drastic decrease in H3K27me3 levels (e.g., the Xq21.33-Xq24 region in ZR-75-1 and MDA-MB-436) (Fig. 6C). On the other hand, much less pronounced variation in H3K27me3 distributions on the Xi was observed when HMEC and WI-38 cells were compared, despite their divergent tissue origins (lung fibroblasts versus mammary epithelial cells) (Fig. 6C). Importantly, in the breast cancer lines, the perturbations were not unique to the Xi, as we also noted aberrant H3K27me3 landscapes across autosomal regions of cancer cells (e.g., Chromosome 17 on Supplemental Fig. S6B), indicating that this is a genome-wide characteristic of tumor cells. Thus, we conclude that both genome-wide and Xi-specific distributions of H3K27me3 are severely disrupted in breast tumor cell lines. Although this is partly due to genomic changes (Xi translocations and regional losses), the Xi epigenomic landscape is clearly disorganized, consistent with our aforementioned observations using IF.

Next, we assessed patterns of H3K4me3 and RNA Pol II around the TSS of X-linked genes, and noted that the escapes identified in each cell line displayed a generally higher enrichment of RNA Pol II and H3K4me3 than X-linked genes that were expressed only from the Xa (Supplemental Fig. S6D,E). Similarly, “cancer-specific” escapes generally exhibited higher enrichment at their TSS in the cell lines where they escaped compared to HMECs (Fig. 6D; Supplemental Fig. S7A) with a few exceptions (e.g., CFP, FLNA, and MOSPD1 in MDA-MB-436 cells displayed no obvious differences in TSS profiles) (Supplemental Fig. S7B). We also noted that “cancer-specific” escapes, such as HDAC8 or NXT2, exhibit additional and/or enlarged H3K4me3 sites in tumor cells when compared to HMEC (Supplemental Fig. S7B). As H3K27me3 is normally rather broadly distributed on the Xi, rather than being TSS centered (Marks et al. 2009; Simon et al. 2013), we examined the local environment of genes that normally escape XCI (e.g., KDMSC and SMCC1A) or are silenced on the Xi (e.g., HUWE1) and found them to display the expected low and high enrichments, respectively (Fig. 6B, center panel).
For "cancer-specific" escapees (TBL1X in ZR-75-1, HDAC8 in MDA-MB-436 and SK-BR-3), no obvious systematic correlation between local H3K27me3 levels and escape/silencing could be seen (Fig. 6B, left and right panels). Although the global disorganization of H3K27me3 domains in tumor cell lines is not necessarily reflected locally at the level of genes, H3K27me3...
disorganization may nevertheless affect long-range regulatory landscapes, creating a context favoring escape in concert with additional events.

Finally, we monitored allele-specific enrichment of H3K4me3, RNA Pol II peaks, and H3K27me3 enrichment across genes with informative SNPs. *HUWE1* revealed exclusively monoallelic enrichment for all three marks, consistent with its silence on the Xi in all lines (Supplemental Fig. S7C), whereas escapes *SMC1A* and *DDX3X* and several “cancer-specific” escapees displayed biallelic H3K4me3 and RNA Pol II, with monoallelic H3K27me3 (Supplemental Fig. S7C,D). Thus, for informative escapees in the three cancer cell lines, H3K27me3 is observed on one allele, whereas both alleles show signs of active transcription (H3K4me3 and RNA Pol II occupancy).

**Figure 6.** Chromatin landscape of the inactive X chromosome is disrupted in breast cancer cell lines. (A) Scheme of H3K27me3 enrichment (ChIP-seq) across the whole X chromosome. Red and green domains represent H3K27me3 and H3K9me3 enriched regions, respectively, as identified in normal human cells (Chadwick 2007). Regional loss of inactive X is indicated (and depicted by gray region). The two main enriched H3K27me3 domains’ loss in ZR-75-1 and MDA-MB-436 are depicted by the two red dotted rectangles. (B) H3K27me3 enrichment is detailed for three regions of the X chromosome carrying genes subjected (S) or escaping XCI (E). (C) Dot plots show variation of H3K27me3 enrichment along the X chromosome (1-Mb bins) of the three tumoral cell lines and WI-38 relative to HMEC. (D) TSS-centered plots (±1.5 kb) show RNA Pol II and H3K4me3 enrichment for the “cancer-specific” escapees (cf. Supplemental Table S1) of each tumoral cell line (red line) and HMEC (green line). The number of genes analyzed is indicated below each plot.
Perturbation of the inactive X chromosome is also found in primary breast tumors

We next assessed whether the Xi is reactivated in primary breast tumors. (A) Z-projections of 3D RNA FISH show representative examples of expression of HDAC8 (red) and ATRX (green) (left) or TBL1X (red) and MAGEA6 (green) (middle) at XIST domains (gray) in healthy breast tissue and invasive ductal carcinoma (IDC; Luminal A Grade III tumor). On the right, Z-projections of super-resolutive 3D immuno-RNA FISH show representative examples of the level of H3K27me3 enrichment (green) and RNA Pol II depletion (red) on XIST RNA domains (gray) in healthy and tumoral breast tissues. Arrowheads indicate the XIST domains. Quantification of RNA Pol II exclusion and H3K27me3 enrichment at XIST domains have been carried out on images acquired with a confocal spinning-disk microscope. Scale bar, 10 µm. (B) Summary of the XIST domain positive (domains in >10% of the nuclei) and negative tumors among the 41 primary breast tumors studied. (C) Summary of the number of tumors harboring HDAC8, ATRX, or TBL1X expression at XIST domain (assessed by RNA FISH). A gene showing expression within the XIST domain in >5% of the nuclei is considered as reactivated in this tumor. (D) The table recapitulates the number of XIST positive tumors with Xi-linked gene reactivation according to their molecular subtypes: Luminal, HER2 amplified, or Basal-like (BCL).

Perturbation of the inactive X chromosome is also found in primary breast tumors

We next assessed whether epigenetic disruption of the Xi also occurs in primary breast tumors. Due to the cellular heterogeneity in such samples, as well as the variable presence of normal stromal cells, we focused on single-cell techniques (IF and RNA FISH) to investigate the Xi. We analyzed seven tumors using a tumor stamp technique with fresh samples (see Methods) to evaluate the degree of enrichment of H3K27me3 at sites of XIST RNA accumulation (Fig. 7A; Supplemental Fig. S8). H3K27me3 enrichment on the Xi in tumors was highly variable, showing almost no enrichment in four of the seven tumors analyzed: T1, T2, T4, and T4meta. This confirmed our observations from cell lines that Xi chromatin status is frequently disrupted in breast cancer. We also noted that H3K27me3 enrichment within a XIST RNA domain was not necessarily accompanied by a depletion of RNA Pol II (e.g., tumors T1 and T2) (Fig. 7A; Supplemental Fig. S8A). We also noted a significant decrease in DNA enrichment at the level of the XIST RNA domain in primary tumors (Supplemental Fig. S8E,F). Taken together, these results demonstrate that the Xi shows significant chromosome disorganization and chromatin disruption in primary breast tumors, similarly to the tumor cell lines described above and that suggesting that disappearance of the Barr body in certain breast cancers is indeed due to epigenetic instability.

We next assessed whether the aberrant chromatin status of the Xi was translated into X-linked gene reactivation by assessing...
XIST together with HDAC8, ATRX, MAGEA6, and TBL1X expression on fresh tumor stamps (including those analyzed above) or tumor-tissue cryosections. These genes were chosen because (1) they are robustly detected by RNA FISH; (2) they are “cancer-specific” escapees in some tumor cell lines (except ATRX and MAGEA6); and (3) HDAC8 and ATRX lie in proximity to each other and to XIST (within a few megabases), thus minimizing their chances of being separated by translocations and facilitating RNA FISH analysis in tumors. We analyzed 41 primary breast tumors with corresponding normal tissue for 15 of them (examples shown in Fig. 7A; Supplemental Fig. S8). Thirty-five tumors were XIST-positive, with at least one XIST RNA domain in ≥10% of nuclei (Fig. 7B). The number, organization, and intensity of XIST RNA domains varied substantially between tumors and even among cells of the same tumor (Supplemental Fig. S8). For X-linked genes, aberrant reactivation from the Xi was considered to occur if ≥5% of nuclei harbored a nascent RNA FISH signal at or within a XIST RNA domain of a given sample. With these criteria, we found 28%, 20%, and 29% of tumors displayed aberrant HDAC8, ATRX, and TBL1X expression from the inactive X, respectively (Fig. 7C). Note that in healthy breast tissue, we never observed >1% of nuclei showing X-linked gene RNA FISH signal within the XIST RNA domain. Furthermore, we did not observe higher degrees of reactivation for any of these three X-linked genes in particular cancer subtypes, although only a limited number of HER2+ and basal-like tumors were analyzed (Fig. 7D). We also analyzed the cancer/testis antigen family 1, member 6 MAGEA6 gene, which is normally silent on both Xa and Xi. None of the primary tumors showed reactivation from the Xi, although in some tumors, MAGEA6 expression was detected from the presumed Xa (Fig. 7A; Supplemental Fig. S8B–D), similarly to our data in breast cancer cell lines. In summary, RNA FISH analysis of 35 XIST-positive primary breast tumors of the luminal, HER2+, and basal-like subtypes, revealed that all three X-linked genes tested, HDAC8, TBL1X, and even ATRX, show Xi reactivation in a significant proportion of tumor cells in stark contrast to the situation in healthy breast tissue from the same patient.

To extend our findings, we analyzed publicly available data for biallelic expression of X-linked genes, using a data set for which both RNA-seq and DNA SNP6 data were available (Shah et al. 2012). After we filtered out tumors of “poor” quality (see Supplemental Methods) and those contaminated by normal cells (Popova et al. 2009), we identified 25 BLC tumor samples with a heterozygous X chromosome, suggesting they likely retained an inactive X or at least some region of the Xi (Supplemental Fig. S9A; Supplemental Table S2). Among these tumors, we identified 183 informative genes, of which 78 were expressed biallelically and 105 monoallelically. Almost half of these biallelically expressed genes are subject to XCI in healthy human cells (Supplemental Fig. S9B; Cotton et al. 2013). Furthermore, in agreement with our findings in the three tumor cell lines, TBL1X, NXT2, and DOCK11 were among the 14 genes that were biallelically expressed in at least two primary breast tumors (Supplemental Fig. S9C). We identified no obvious correlation between the degree of “cancer-specific” escape from XCI and the BRCAness of the tumor (as defined in Popova et al. 2012; Supplemental Table S2).

In summary, our analysis of Xi transcriptional status in a total of about 140 primary breast tumors of the luminal, HER2+, and basal-like subtypes, using both RNA FISH and RNA-seq analyses, revealed that multiple X-linked genes are reactivated on the inactive X chromosome.

Discussion

We have conducted an in-depth investigation of the nuclear organization, chromatin status, and chromosom-wide transcriptional activity of the inactive X chromosome in breast cancer cell lines and primary tumor samples. We can conclude that a frequent cause of Barr body loss in breast cancer is due to the global perturbation of its nuclear organization and disruption of its heterochromatic structure. Furthermore, the aberrant epigenomic landscapes we have uncovered for the Xi in breast cancer cells are accompanied by a significant degree of sporadic gene reactivation, which in some cases can lead to aberrant dosage at the protein level (Supplemental Fig. S10A).

Epigenetic erosion of the Barr body in breast cancer

Epigenetic perturbations of the inactive X chromosome were found at multiple levels in breast cancer. Based on microscopy, XIST RNA coating was often found to be highly dispersed, with variable H3K27me3 enrichment, and a marked absence of an RNA Pol II-depleted nucleolar compartment. Based on ChIP-seq, abnormal presence of both RNA Pol II and H3K4me3 was observed at “cancer-specific” escapees, reminiscent of the chromatin organization of the normally escapes from XCI in noncancer cells (Kucera et al. 2011; Cotton et al. 2013). Importantly, however, virtually all informative “cancer-specific” escapees displayed simultaneously repressive (H3K27me3) and active (H3K4me3, RNA Pol II recruitment) chromatin marks (see Supplemental Fig. S7D), suggestive of bivalent chromatin, as observed in ES cells (Bernstein et al. 2006), which may reflect, or even underlie, metastable states of gene expression from the Xi in a cancer context. The Xi was also severely perturbed at a more global chromatin level, with aberrant distributions of H3K27me3 and acetylation of H3 and H4 present in interphase breast cancer cells. The disruption of H3K27me3 domains that we observed based on ChIP-seq in breast cancer cell lines may reflect the nuclear disorganization of the Xi, as it has been shown that H3K27me3 enriched domains in normal cells tend to be clustered together in interphase and most likely participate in the specific chromosomal and nuclear organization of the Barr body (Chadwick and Willard 2004). Nevertheless, despite these global and local epigenetic perturbations in all the breast cancer cell types examined, the Xi could still be distinguished from the Xa. For example, although the degree of enrichment for H3K27me3 on the Xi is lower in cancer cells when compared to HMEC and WI-38 cells, it is still higher than the mean enrichment found over the rest of the genome (Fig. 2B; Supplemental Fig. S10B). Similarly, although exclusion of Cot-1 RNA, RNA Pol II, and euchromatic marks is not complete on the Xi in cancer samples, some degree of exclusion is nevertheless detectable in a subset of cells. Furthermore, “cancer-specific” escapees (like normal escapees) were never expressed to the same levels as their counterparts on the active X.

Possible causes of the epigenetic instability of the inactive X chromosome in breast cancer

Epigenetic instability of the Xi appears to occur across a broad spectrum of breast cancer types with no obvious specificities for particular molecular subclasses. For example, elevated genetic instability, such as in BRCA1 null and basal-like breast tumors (Richardson et al. 2006; Vincent-Salomon et al. 2007) cannot explain the marked epigenetic instability that we found in all subtypes. We believe that the underlying causes of the structural
and transcriptional lability of the Xi in cancer are probably a result of both genetic and epigenetic defects. For example, the slightly lower levels of XIST expression that we observed in most cases might lead to less efficient chromosome coating and contribute to the disruption of the silent nuclear compartment normally present in somatic cells (Chaumeil et al. 2006; Clemson et al. 2006), as well as to the aberrant distribution of H3K27me3 and other chromatin marks. Furthermore, the precise combination of epigenetic factors that ensure the inactive state of different genes on the inactive X chromosome in somatic cells is still very much an open question. Indeed, our study revealed that the rather global epigenetic misregulation in tumor cells results in rather sporadic X-linked gene reactivation, and escape from silencing may be dependent on a gene's local environment, as neighboring genes can behave very differently in a cancer context. For example, the NXT2 gene was found to show aberrant transcription, whereas its close neighbor, NUP62CL, remained silent in MDA-MB-436 cells, although both lie in a non-XIST-coated/H3K27me3 depleted region of the Xi (Supplemental Table S1).

Consequences of Xi erosion in breast cancer cells

The epigenetic instability of the Xi in breast cancer, which can result in aberrant X-linked gene expression, might in some cases contribute to a selective advantage for cancer cells. Indeed, several “cancer-specific” escapees identified here have previously been shown to be involved in cancer, such as HDAC8, which is implicated in cellular transformation (Oehme et al. 2009) and metastasis formation (Park et al. 2011). TBL1X, for which we demonstrated increased protein dosage in the context of its aberrant reactivation from the Xi, belongs to a complex with HDAC3 that is directly linked to several forms of cancer (Spurling et al. 2008; López-Soto et al. 2009; Kim et al. 2010; Müller et al. 2013; Miao et al. 2014). Aberrant dosage of such X-linked chromatin-associated factors could easily be imagined to lead to pleiotropic effects in a cancer context, promoting or enhancing more genome-wide misregulation. Further studies will be required to explore the extent to which X-linked gene reactivation might contribute to cancer progression.

Importantly, in addition to the aberrant reactivation of genes on the inactive X, aberrant silencing of several genes that normally escape XCI, such as RAB9A, BCOR, RPL39, or PNPLA4 was also observed in tumor cell lines. BCOR mutations have already been implicated in some cancers (Zhang et al. 2012). Aberrant repression of such genes in a cancer context might be due to sporadic epimutation or to impaired protection from XCI through perturbation of boundary elements (Filippova et al. 2005). Finally, we also showed that abnormal activation of cancer/testis Antigen genes, which are known to be aberrantly expressed in cancer, was from the active rather than the inactive X chromosome in one case (MAGEA6), pointing to differences in the stability of silent genes on the active versus the inactive X chromosomes in cancer.

Consequences of genetic instability on the epigenetic status of the Xi in cancer cells

Our study also reveals how chromosomal rearrangements, such as deletions or translocations can have an impact on the epigenetic status of a chromosome through loss of the XIC from an inactive X fragment and/or juxtaposition of the XIC to an autosome. We found such a scenario in the MDA-MB-436 cell line, where loss of the XIC from an Xi fragment resulted in reduced H3K27me3 enrichment on the Xi, as expected from previous reports demonstrating that PRC2 is recruited (directly or indirectly) to the Xi via XIST RNA (Wutz et al. 2002; Plath et al. 2004; Maenner et al. 2010). However, the H3K27me3 profile on this Xi fragment is not equivalent to a euchromatin region, indicating that other mechanisms may act to maintain an intermediate heterochromatic organization. Furthermore, loss of XIST RNA coating and reduced H3K27me3 was not sufficient to result in notably higher rates of sporadic gene reactivation of the inactive X-chromosome fragment when compared to Xi fragments carrying an XIC and expressing XIST (Supplemental Fig. S10A). This is presumably because other marks, such as hypoacetylation of H4, hypomethylation of H3K4, and promoter DNA methylation, are not fully perturbed and can propagate the inactive state. Thus, although XIST RNA and PRC2-associated chromatin changes may participate in maintaining the inactive state, they do not appear to be essential in the context of this particular cell line. We also made the intriguing observation that in X-autosome translocations involving an Xi fragment still carrying an XIC and expressing XIST RNA, H3K27me3 enrichment could be found to spread into the autosomal sequences adjacent to the XIC (for example in the SK-BR-3 and MDA-MB-436 cell lines) (Fig. 3C). Although we were not able to evaluate whether this results in aberrant gene silencing, such a spread of heterochromatin into autosomal regions as previously shown (Cotton et al. 2014) could clearly have important implications in a cancer context by inducing functional LOH for critical genes such as tumor suppressors.

In conclusion, the perturbed transcriptional and chromatin status of the inactive X chromosome that we have identified in the context of breast cancer opens up several important clinical perspectives. Today, there is still no rapid and efficient way to evaluate the epigenetic instability of tumor cells in a clinical context (Portela and Esteller 2010). In theory, detection of X-linked gene reactivation and aberrant chromatin status using IF and RNA FISH in breast tumors could provide valuable biomarkers to assess epigenetic status and/or to evaluate responsiveness of tumors to drug treatments (Huang et al. 2002). Whether the same degree of Xi epigenetic instability will be found in other types of cancer remains an interesting question for the future.

Methods

RNA, DNA FISH, and immunofluorescence

For XIST RNA FISH, a combination of two probes covering 16 kb of XIST mRNA was used (Okamoto et al. 2011). For nascent transcript detection by RNA FISH, the following BAC (CHORI) probes were used: HDAC8 (RP11-1021B19), TBLIX (RP11-451G24), ATRX (RP11-42M11), HUWE1 (RP11-155O24), and KDMSC (RP11-258C19). The correct chromosomal location of BACs was first verified using DNA FISH on metaphase spreads. A FISH probe for MAGEA6 was generated by cloning the genomic sequence in pCR-XL-TOPO vector. Human Cot-1 DNA (Invitrogen) was used for Cot-1 RNA FISH. Probes were labeled by nick translation (Vysis) with Spectrum Red-dUTP, Spectrum Green-dUTP, or Cy5-dUTP following the manufacturer’s instructions. RNA and DNA FISH were performed as described previously (Chaumeil et al. 2008). For more details see Supplemental Methods.

Microscopy

Images were generated using a Nikon confocal spinning disk microscope fitted with a 60x/1.4 OIL DIC N2 PL APO VC objective.
For super resolution imaging, structured illumination (3D-SIM) was performed using a DeltaVision OMX microscope (GE Healthcare).

**Human SNP Array 6.0 DNA and nascent RNA experiments**

**DNA copy number profiles**

Genomic profiling was performed at Institut Curie using Affymetrix Human SNP Array 6.0; cell files were processed by Genotyping Console 3.0.2 (Affymetrix, reference model file HapMap270, version 29). Human SNP Array 6.0 data were mined using the previously described and validated GAP method (Popova et al. 2009). Segmental absolute copy numbers and allelic contents (major allele counts) were detected. R scripts and full details of the application are available at http://bioinfo-out.curie.fr/projects/snp_gap and have been previously reported (Popova et al. 2009). For more details see Supplemental Methods.

**Nascent RNA allelic expression**

Preparation of samples and analysis of nascent RNA were performed as described previously (Gimelbrant et al. 2007). Briefly, we purified nuclei of assessed cell lines (Nuclei Pure Isolation Kit, Sigma) and subsequently purified nuclear RNA (by classical phenol/chloroform extraction). Then, we hybridized cDNA obtained by reverse transcription of nuclear RNA of each sample onto Affymetrix Human SNP Array 6.0. Data was normalized by Genotyping console, and raw single-SNP intensities were taken as allelic expression of corresponding genes. Each SNP was characterized by (1) global expression level score; (2) allelic expression ratio score; and (3) genomic status (loss or retention of heterozygosity score), which were summarized into a biallelic and monoallelic expression status. Genome-wide biallelic and monoallelic expression profiles were obtained by cumulating SNP status in a 50-SNP window and at gene level.

**Primary tumors**

A hematein-eosin-safran (HES)–stained tissue section was made in each primary tumor to evaluate tumor cellularity and differentiation. Characterization of the tumor samples was completed by the determination of estrogen receptor, progesterone receptor, ERBB2, cytokeratin 5/6, and epidermal growth factor receptor (EGFR) status determined by immunohistochemistry done according to previously published protocols (Azoulay et al. 2005). All experiments were performed in accordance with the French Bioethics Law for super resolution imaging, structured illumination (3D-SIM) was performed using a DeltaVision OMX microscope (GE Healthcare).

**Data access**

All high-throughput data from this study have been submitted to the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE62907.

**Acknowledgments**

We would like to thank all members of the Heard team for helpful discussions and in particular Julie Chaumeil and Simao da Rocha for critical reading of the manuscript. We would also like to thank Michel Wassef and Raphael Margueron for discussions and feedback on this work. Support is gratefully acknowledged from l’Association pour la Recherche sur le Cancer (ARC) (post-doctoral fellowship to R.C.); FRM (Equipe FRM to E.H. from 2006–2009); Equipe labellisée “La Ligue Contre le Cancer” (Equipe Labellisée à E.H. since 2011); EU FP7 MODHEP EU Grant no. 259743 (to E.H.); Labex DEEP (ANR-11-LBX-00044) part of the IDEX Idex PSL (ANR-10-IDEX-0001-02 PSL); and ERC Advanced Investigator Award no. 250367. This work was also supported by the AVIESAN-ITMO Cancer-INCa grant “Epigenomics of breast cancer” (E.H., H.G., and M.-H.S.). Work in the laboratory of H.G. was supported by the Agence Nationale de la Recherche (ANR-10-LABX-0030-INRT and ANR-10-IDEX-0002-02), the Ligue Contre le Cancer (H.G.; Equipe Labellisée), SATT Conectus Alsace, and the Institut Nationale du Cancer. The authors greatly acknowledge the PICT-BIBAS@BDD (UMR3215/U934) Imaging facility of the Institut Curie, the cytometry platform of the Institut Curie, and the “Centre de Ressources Biologiques” for access to the tumor materials.

**References**

Agrelo R, Wutz A. 2010. ConteXt of change—X inactivation and disease. *EMBO Mol Med* 2: 6–15.

Azoulay S, Laé M, Fréneaux P, Merle S, Al Ghuzlan A, Cneeker C, Rosty C, Klijnjenko J, Sigal-Zafrani B, Salmon R, et al. 2005. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. *Mod Pathol* 18: 1623–1631.

Barr ML, Moose KL. 1957. Chromosomes, sex chromatin, and cancer. *Proc Can Cancer Conf* 2: 3–16.

Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitell S, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. 2001. The immune dysregulation, polycystic nephropathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nat Genet* 27: 20–21.

Bernstein BE, Mikkelsen TS, Lien A,空前未有的, Wutz A. 2009. ConteXt of change—X inactivation and disease. *EMBO Mol Med* 2: 6–15.

Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitell S, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. 2001. The immune dysregulation, polycystic nephropathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nat Genet* 27: 20–21.

Bernstein BE, Mikkelsen TS, Lien A,空前未有的, Wutz A. 2009. ConteXt of change—X inactivation and disease. *EMBO Mol Med* 2: 6–15.
Clemson CM, Hall LL, Byron M, McNeill J, Lawrence JB. 2006. The X chromosome is organized into a gene-rich outer rim and an internal core containing silenced nongenic sequences. Proc Natl Acad Sci 103: 7688–7693.

Cotton AM, Chen YY, Light N, Adoue V, Pastinen T, Brown CJ. 2013. Analysis of expressed SNPs identities variable extents of expression from the human inactive X chromosome. Genome Biol 14: R122.

Cotton AM, Chen LY, Wasserman WM, Kobor MS, Brown CJ. 2013. Spread of X-chromosome inactivation into autosomal sequences: role for DNA elements, chromatin features and chromosomal domains. Hum Mol Genet 23: 1211–1223.

Csankovszki G, Panning B, Bates B, Pehson JR, Jaenisch R. 1999. Conditional inactivation of Xist disrupts histone macroH2A localization but not maintenance of X inactivation. Nat Genet 22: 323–324.

Csankovszki G, Nagy A, Jaenisch R. 2001. Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation. J Cell Biol 155: 775–784.

De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, Kelly TK, Yang X, Liang G, Jones PA. 2012. DNA methylation screening identifies drivers epigenetic events of cancer cell survival. Cancer Cell 21: 655–667.

Elshendy SE, Green AL, Rakha EA, Powe DG, Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar MA, et al. 2009. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer 115: 3802–3809.

The ENCODE Project Consortium. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57–74.

Filippova GN, Cheng MK, Moore JM, Truong JP, Hu YJ, Nguyen DK, Tsujiya KD, Distecho CM. 2005. Boundaries between chromosomal domains of X inactivation and escape bind CTCF and lack Cpg methylation during early development. Dev Cell 8: 31–42.

Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A, Mok SC, The ENCODE Project Consortium. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57–74.

Nakagawa M, Oda Y, Eguchi T, Ishiama Y, Tao T, Hoshino M, Inukai Y, Ono M, Kuwano M, Tanaka M, et al. 2007. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 19: 769–774.

O’Donovan PJ, Livingston DM. 2010. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 31: 961–967.

Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp Schneider A, Westermann F, Ulrich SM, von Deimling A, et al. 2009. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 15: 91–99.

Okamoto I, Patrat C, Théopiet D, Peynot N, Fauque P, Daniel N, Diabangouaya P, Wolf JP, Renard JP, Duranthon V, et al. 2011. Eutherian mammals use diverse strategies to initiate X-chromosome inactivation during development. Nature 472: 370–374.

Pageau GJ, Hall LL, Ganesan S, Livingston DM, Lawrence JB. 2007. The disappearing Barr body in breast and ovarian cancers. Nat Rev Cancer 7: 525–532.

Park SY, Jun JA, Jeong KJ, Heo HJ, Sohn JS, Lee HY, Park CG, Kang J, Jiang N. 2011. Histone deacetylases 1 and 6 and 8 are critical for invasion in breast cancer. Oncol Rep 25: 2097–2105.

Persin CM, Sentiljev T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. 2000. Molecular portraits of human tumors. Nature 406: 747–752.

Perry M. 1972. Evaluation of breast tumour sex chromatin (Barr body) as an index of survival and response to pituitary ablation. Br J Surg 59: 731–734.

Plath K, Talbott D, Harmer KM, Otte AP, Yang TP, Jaenisch R, Panning B. 2004. Developmentally regulated alterations in Polycomb repressive complex 2 proteins on the inactive X chromosome. J Cell Biol 167: 1025–1035.

Popova T, Manie E, Rigaill G, Barillot E, Stern MH. 2009. genome-wide mapping of DNA elements, chromatin features and chromosomal domains. Abs 3165.

Pushker A, D’Hondt E, Bielaszewska J, Esau C, Kozlowski R, et al. 2012. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Cancer Res 15: 91–99.

Rohan A, Leboutin S, Tourneur F, Schmitz H, Chaligne C, 1994. Role for DNA elements, chromatin features and chromosomal domains. Hum Mol Genet 3: 452–459.

Robertson KD. 2011. DNA methylation screening identifies drivers epigenetic events of cancer cell survival. Cancer Cell 21: 655–667.

Roh J, Yoo JH, Lee SH, Jun CW, Jeong SB, Park YJ, Min GB, et al. 2011. CT-X antigen concentration on the inactive X chromosome. Dev Genet 39: 342–352.

Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse D, et al. 2010. DNA copy number alterations in human breast cancer. Nature 468: 803–809.

Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse D, et al. 2010. DNA copy number alterations in human breast cancer. Nature 468: 803–809.
adopts a unique three-dimensional conformation that is dependent on Xist RNA. Genes Dev 25: 1371–1383.
Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW, Giardina C. 2008. HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog 47: 137–147.
Turner NC, Reis-Filho JS. 2006. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25: 5846–5853.
Vincent-Salomon A, Ganem-Elbaz C, Manié E, Raynal V, Sastre-Garau X, Stoppa-Lyonnet D, Stern MH, Heard E. 2007. X inactive–specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors. Cancer Res 67: 5134–5140.
Wutz A, Rasmussen TP, Jaenisch R. 2002. Chromosomal silencing and localization are mediated by different domains of Xist RNA. Nat Genet 30: 167–174.
Xiao C, Sharp JA, Kawahara M, Davalos AR, Difilippantonio MJ, Hu Y, Li W, Cao L, Buetow K, Ried T, et al. 2007. The XIST noncoding RNA functions independently of BRCA1 in X inactivation. Cell 128: 977–989.
Yildirim E, Kirby JE, Brown DE, Mercier FE, Sadreyev RJ, Scadden DT, Lee JT. 2013. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell 152: 727–742.
Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, Ulyanov A, Wu G, Wilson M, Wang J, et al. 2012. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481: 329–334.
Zink D, Fischer AH, Nickerson JA. 2004. Nuclear structure in cancer cells. Nat Rev Cancer 4: 677–687.

Received October 28, 2014; accepted in revised form January 28, 2015.